FeelTect, a medical technology company, has secured $7,340,918 in new investment capital from investors. This funding round is set to accelerate the development and market penetration of its flagship product, Tight Alright. FeelTect's technology, Tight Alright, is a pressure sensing, connected-health device designed for measuring and monitoring sub-bandage pressure during compression therapy. Its primary application is for the millions of people worldwide suffering from venous leg ulcers (VLUs).
Compression therapy is a well-established treatment for VLUs, but its effectiveness is highly dependent on precise application. If compression is applied too loose, it proves ineffective, while if it is too tight, it poses a significant danger to the patient. Studies have indicated that even experienced healthcare professionals face considerable challenges in achieving a targeted pressure with current products. Tight Alright addresses this critical need by aiming to improve the application and maintenance of evidence-based compression therapy, thereby ensuring patient safety and reducing healing times.
The recently acquired capital will be instrumental in FeelTect’s strategic growth initiatives. The company plans to use the funds to expand its operational capabilities, which includes growing its expert team, advancing its product development roadmap, and scaling its market reach to bring Tight Alright to a wider audience. This investment underscores confidence in FeelTect’s innovative approach to an underserved area of wound care.
Looking ahead, this significant funding positions FeelTect to solidify its presence in the connected-health device market and continue its commitment to enhancing patient outcomes globally. The company aims to further its mission of making effective and safe compression therapy universally accessible, thereby improving the quality of life for VLU patients.
.png&w=3840&q=75)
